Gilead seeks FDA approval of HIV-fighter elvitegravir

Gilead Sciences Inc. is looking to add to its HIV-fighting arsenal, seeking approval Wednesday for one of the four ingredients in its once-a-day Quad pill.

Foster City-based Gilead (NASDAQ: GILD) filed a new drug application Wednesday with the Food and Drug Administration to market elvitegravir to people with the AIDS virus who have used other treatments.

Elvitegravir is combined with emtricitabine and tenofovir -- two compounds that together form Gilead's Truvada -- and a new Gilead-developed booster, called cobicistat, to form the Quad pill.